Pharmacokinetic Study of Vadadustat and High-Resolution Mass Spectrometric Characterization of its Novel Metabolites in Equines for the Purpose of Doping Control
- 15 December 2022
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Drug Metabolism
- Vol. 23 (10) , 850-865
Abstract
Background: Vadadustat, a hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) inhibitor, is a substance which carries a lifetime ban in both horse racing and equestrian competition. A comprehensive metabolic study of vadadustat in horses has not been previously reported. Objective: Metabolism and elimination profiles of vadadustat in equine plasma and urine were studied for the purpose of doping control. Methods: A nasoesophageal administration of vadadustat (3 g/day for 3 days) was conducted on three thoroughbred mares. Potential metabolites were comprehensively detected by differential analysis of full-scan mass spectral data obtained from both in vitro studies with liver homogenates and post-administration samples using liquid chromatography high-resolution mass spectrometry. The identities of metabolites were further substantiated by product ion scans. Quantification methods were developed and validated for the establishment of the excretion profiles of the total vadadustat (free and conjugates) in plasma and urine. Results: A total of 23 in vivo and 14 in vitro metabolites (12 in common) were identified after comprehensive analysis. We found that vadadustat was mainly excreted into urine as the parent drug together with some minor conjugated metabolites. The elimination profiles of total vadadustat in post-administration plasma and urine were successfully established by using quantification methods equipped with alkaline hydrolysis for cleavage of conjugates such as methylated vadadustat, vadadustat glucuronide, and vadadustat glucoside. Conclusion: Based on our study, for effective control of the misuse or abuse of vadadustat in horses, total vadadustat could successfully be detected for up to two weeks after administration in plasma and urine.Keywords
Funding Information
- JRA, Japan Racing Association (2022)
This publication has 64 references indexed in Scilit:
- In Vitro Glucuronidation of the Antibacterial Triclocarban and Its Oxidative MetabolitesDrug Metabolism and Disposition, 2012
- HIF prolyl hydroxylase inhibitors for anemiaExpert Opinion on Investigational Drugs, 2011
- Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemiaExpert Opinion on Therapeutic Patents, 2010
- Challenges in the indirect quantitation of acyl‐glucuronide metabolites of a cardiovascular drug from complex biological mixtures in the absence of reference standardsBiomedical Chromatography, 2009
- UDP-Glucuronosyltransferase 1A1 Is the Principal Enzyme Responsible for Etoposide Glucuronidation in Human Liver and Intestinal Microsomes: Structural Characterization of Phenolic and Alcoholic Glucuronides of Etoposide and Estimation of Enzyme KineticsDrug Metabolism and Disposition, 2007
- New agents that stimulate erythropoiesisBlood, 2006
- Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene RegulationMolecular and Cellular Biology, 2003
- Cooperative Interaction of Hypoxia-inducible Factor-2α (HIF-2α) and Ets-1 in the Transcriptional Activation of Vascular Endothelial Growth Factor Receptor-2 (Flk-1)Journal of Biological Chemistry, 2003
- Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in SignalingScience, 2002
- The metabolic fate of 14C‐oxaprotiline · HCl in man. III. Stereospecific dispositionBiopharmaceutics & Drug Disposition, 1984